Secondary mutations in MEK [22] and activation of downstream MEK1 [23] following escape from single agent BRAF inhibition led to the investigation of the current SOC therapy for BRAFV600E/K-mutant melanoma, dual dabrafenib and trametinib treatment. This evidence concerns the gene MAP2K7 and melanoma.